Literature DB >> 10925316

NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis.

P Rameshwar1, R Narayanan, J Qian, T N Denny, C Colon, P Gascon.   

Abstract

Immune-mediated mechanisms have been implicated in the etiology of idiopathic bone marrow fibrosis (IMF). However, the mechanism remains poorly defined. Compared with healthy controls, IMF monocytes are overactivated, with increased production of TGF-beta and IL-1. TGF-beta is central to the progression of fibrosis in different organs. In the lung, fibrosis is associated with up-regulation of TGF-beta-inducible genes. Because IL-1 and TGF-beta have pro- and antiinflammatory properties and neither appears to regulate the high levels of each other in IMF, we studied the mechanism of this paradigm. We focused on the role of RelA, a subunit of the transcription factor, NF-kappaB that is associated with inflammatory responses. We transiently knocked out RelA from IMF monocytes with antisense oligonucleotides and showed that RelA is central to IL-1 and TGF-beta production and to the adhesion of IMF monocytes. Because the NF-kappaB family comprises subunits other than RelA, we used aspirin and sodium salicylate to inhibit kinases that activate NF-kappaB and showed effects similar to those of the RelA knockout system. It is unlikely that RelA could be interacting directly with the TGF-beta gene. Therefore, we determined its role in TGF-beta production and showed that exogenous IL-1 could induce TGF-beta and adherence of IMF monocytes despite the depletion of NF-kappaB. The results indicate that IL-1 is necessary for TGF-beta production in IMF monocytes, but NF-kappaB activation is required for the production of endogenous IL-1. Initial adhesion activates NF-kappaB, which led to IL-1 production. Through autocrine means, IL-1 induces TGF-beta production. In total, these reactions maintain overactivation of IMF monocytes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10925316     DOI: 10.4049/jimmunol.165.4.2271

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

2.  Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.

Authors:  Giovanni Barosi; Elisabetta Gattoni; Paola Guglielmelli; Rita Campanelli; Fabio Facchetti; Simona Fisogni; Judith Goldberg; Roberto Marchioli; Ronald Hoffman; Alessandro M Vannucchi
Journal:  Am J Hematol       Date:  2010-08       Impact factor: 10.047

3.  NADPH oxidase inhibition ameliorates cardiac dysfunction in rabbits with heart failure.

Authors:  Yu Liu; He Huang; Wenfang Xia; Yanhong Tang; Haitao Li; Congxin Huang
Journal:  Mol Cell Biochem       Date:  2010-06-22       Impact factor: 3.396

Review 4.  An immune dysregulation in MPN.

Authors:  Giovanni Barosi
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 5.  Proteasomal regulation of pulmonary fibrosis.

Authors:  Curtis H Weiss; G R Scott Budinger; Gökhan M Mutlu; Manu Jain
Journal:  Proc Am Thorac Soc       Date:  2010-02

6.  Activin A is an autocrine activator of rat pancreatic stellate cells: potential therapeutic role of follistatin for pancreatic fibrosis.

Authors:  N Ohnishi; T Miyata; H Ohnishi; H Yasuda; K Tamada; N Ueda; H Mashima; K Sugano
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

7.  Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats.

Authors:  Wenyuan Zhao; Tieqiang Zhao; Yuanjian Chen; Robert A Ahokas; Yao Sun
Journal:  Mol Cell Biochem       Date:  2008-06-26       Impact factor: 3.396

Review 8.  Therapy with JAK2 inhibitors for myeloproliferative neoplasms.

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Hematol Oncol Clin North Am       Date:  2012-08-21       Impact factor: 3.722

9.  Increased TG2 expression can result in induction of transforming growth factor beta1, causing increased synthesis and deposition of matrix proteins, which can be regulated by nitric oxide.

Authors:  Dilek Telci; Russell John Collighan; Huveyda Basaga; Martin Griffin
Journal:  J Biol Chem       Date:  2009-08-05       Impact factor: 5.157

Review 10.  The complex regulation of TGF-β in cardiovascular disease.

Authors:  Santiago Redondo; Jorge Navarro-Dorado; Marta Ramajo; Úrsula Medina; Teresa Tejerina
Journal:  Vasc Health Risk Manag       Date:  2012-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.